Lab Genomics has forged a partnership to distribute Contextual Genomics’ FOLLOW IT liquid biopsy cancer testing.
The FOLLOW IT panel is a multiplex, NGS genomic assay designed for rapid deployment into laboratories.
Under the agreement, Lab Genomics will provide Contextual Genomics’ the next generation sequencing (NGS) based cell-free circulating tumour DNA (ctDNA) cancer genomic testing to patients in Southern California and other parts of the US.
Contextual Genomics CEO Michael Ball said: “The availability of quality-assured cost-effective rapid turnaround time ctDNA testing as a result of this partnership will be of tremendous benefit to many patients suffering from solid tumour cancers, avoiding the need for more invasive tissue biopsies.
“We look forward to working with Lab Genomics to bring this more precise personalised care to cancer patients within their territory.”
The mutation status of cell-free circulating tumour is evaluated by FOLLOW IT. It identifies the somatic mutations that have the maximum potential to impact patient treatment.
Lab Genomics founder Leena Dalal said: “At Lab Genomics, our mission is to deliver a suite of unmatched molecular diagnostic services to our customers, to provide preventive, predictive, personalised services.
“This partnership with Contextual Genomics, adding FOLLOW IT liquid biopsy cancer testing for our customers, provides a critical less invasive alternative testing option for cancer patients where tissue biopsy is difficult or not available.
“We look forward to continuing to support the best quality of life possible for all patients and FOLLOW IT will be an important part of our oncology offering.”